Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2

Conditions

Leukemia, Myeloid, Acute 31Burkitt Lymphoma 12Myelodysplastic Syndromes 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myeloproliferative Disorders 6Leukemia, Biphenotypic, Acute 5Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Leukemia 3Down Syndrome 3Blast Crisis 3Sarcoma, Myeloid 2Recurrence 2Lymphoma, Follicular 2Plasmablastic Lymphoma 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5fludarabine 5Whole-Body Irradiation 4Busulfan 4Biopsy 4Specimen Handling 3Injections 3Cytarabine 3venetoclax 2decitabine and cedazuridine drug combination 2Tacrolimus 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporine 2CPX-351 2Azacitidine 2treosulfan 1peginterferon alfa-2b 1olutasidenib 1itacitinib 1canakinumab 1aldesleukin 1X-Rays 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × Cytarabine × 30 days × Clear all
NCT03672539 2026-05-20

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03896269 2026-05-20

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1 Recruiting
38 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT06928662 2026-05-15

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
36 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡